Reviewed listing: NYSE:PEN · Analysis dated Oct 19, 2026
The underlying information has changed since this analysis. This earlier assessment has not yet been updated for those changes. It refers to the analysis date and original reviewed price shown here.
How does the company make money?
Penumbra makes medical devices that physicians use, among other things, to remove blood clots. Hospitals and medical providers purchase the products for use in their treatments.
What supports the business?
Revenue and operating cash flow increased. The business remains profitable, although costs related to the planned acquisition are a burden.
What could improve?
Greater use of medical devices could expand the business. For the stock, it is also currently crucial whether the planned acquisition goes through and how the acquirer’s shares perform.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
320.86 USD cannot be convincingly justified solely by the earnings reported to date. The acquisition value includes the buyer’s shares and can fluctuate; therefore, the price assessment remains open.
What is the main risk?
If the acquisition fails or is delayed, the share price may fall significantly. Product issues, competition, and medical approvals also affect the standalone business.
What is the overall assessment?
Watch: Penumbra is growing and generating cash. At 320.86 USD, however, the valuation depends heavily on the planned acquisition; the stated 374 USD are not a guaranteed cash payment per share.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in